中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
6期
612-614
,共3页
李洁%王扬天%许一新%陈晔%王坚%彭丽
李潔%王颺天%許一新%陳曄%王堅%彭麗
리길%왕양천%허일신%진엽%왕견%팽려
2型糖尿病%二甲双胍%利拉鲁肽%血糖
2型糖尿病%二甲雙胍%利拉魯肽%血糖
2형당뇨병%이갑쌍고%리랍로태%혈당
Type 2 diabetes mellitus%Metformin%Liraglutide%Blood glucose
目的 探讨二甲双胍治疗的2型糖尿病(T2DM)患者中加用利拉鲁肽的效果.方法 20例T2DM患者口服最大耐受剂量二甲双胍至少2个月,加用利拉鲁肽0.6 mg,治疗1周后改为1.2 mg,治疗3个月.观察治疗前后血糖、糖化血红蛋白、胰岛功能、血脂、体质量的差异.结果 治疗前后比较,空腹血糖[(8.9±1.4) mmol/L与(6.9±1.0) mmol/L,t=5.951,P＜0.01],餐后血糖[(14.4±1.5)mmol/L与(10.4±1.4) mmol/L,t=8.878,P＜0.01],糖化血红蛋白[(8.7±1.3)％与(7.6±1.1)％,t=4.860,P＜0.01]、空腹C肽[(1.7±0.6)mg/L与(2.9±1.1) mg/L,t=5.752,P＜0.01]、餐后2hC肽[(5.0±2.3) mg/L与(10.2±3.5)mg/L,t =5.667,P＜0.01],差异均有统计学意义,以及血脂和体质量水平均与治疗前相比差异有统计学意义(P均＜0.01).结论 利拉鲁肽可持续有效地控制T2DM患者的血糖,减轻体质量,改善血脂水平和胰岛B细胞功能,且发生低血糖的风险低.
目的 探討二甲雙胍治療的2型糖尿病(T2DM)患者中加用利拉魯肽的效果.方法 20例T2DM患者口服最大耐受劑量二甲雙胍至少2箇月,加用利拉魯肽0.6 mg,治療1週後改為1.2 mg,治療3箇月.觀察治療前後血糖、糖化血紅蛋白、胰島功能、血脂、體質量的差異.結果 治療前後比較,空腹血糖[(8.9±1.4) mmol/L與(6.9±1.0) mmol/L,t=5.951,P＜0.01],餐後血糖[(14.4±1.5)mmol/L與(10.4±1.4) mmol/L,t=8.878,P＜0.01],糖化血紅蛋白[(8.7±1.3)％與(7.6±1.1)％,t=4.860,P＜0.01]、空腹C肽[(1.7±0.6)mg/L與(2.9±1.1) mg/L,t=5.752,P＜0.01]、餐後2hC肽[(5.0±2.3) mg/L與(10.2±3.5)mg/L,t =5.667,P＜0.01],差異均有統計學意義,以及血脂和體質量水平均與治療前相比差異有統計學意義(P均＜0.01).結論 利拉魯肽可持續有效地控製T2DM患者的血糖,減輕體質量,改善血脂水平和胰島B細胞功能,且髮生低血糖的風險低.
목적 탐토이갑쌍고치료적2형당뇨병(T2DM)환자중가용리랍로태적효과.방법 20례T2DM환자구복최대내수제량이갑쌍고지소2개월,가용리랍로태0.6 mg,치료1주후개위1.2 mg,치료3개월.관찰치료전후혈당、당화혈홍단백、이도공능、혈지、체질량적차이.결과 치료전후비교,공복혈당[(8.9±1.4) mmol/L여(6.9±1.0) mmol/L,t=5.951,P＜0.01],찬후혈당[(14.4±1.5)mmol/L여(10.4±1.4) mmol/L,t=8.878,P＜0.01],당화혈홍단백[(8.7±1.3)％여(7.6±1.1)％,t=4.860,P＜0.01]、공복C태[(1.7±0.6)mg/L여(2.9±1.1) mg/L,t=5.752,P＜0.01]、찬후2hC태[(5.0±2.3) mg/L여(10.2±3.5)mg/L,t =5.667,P＜0.01],차이균유통계학의의,이급혈지화체질량수평균여치료전상비차이유통계학의의(P균＜0.01).결론 리랍로태가지속유효지공제T2DM환자적혈당,감경체질량,개선혈지수평화이도B세포공능,차발생저혈당적풍험저.
Objective To investigate the therapeutic effect of liraglutide on glycemic control in metformin-treated patients with type 2 diabetes mellitus (T2DM).Methods Twenty patients with T2DM by maximum tolerated dose of mefformin in this study.For at least 3 months,participants were treated by addingliraglutide.After 1 week,the dosage of liraglutide was increased to 1.2 mg for 3 months from 0.6 mg.Patients' blood glucose,glycosylated hemoglobin(HbA1c),islet function,blood lipid and body weight were observed.Results Compared with before treatment,there were significant change of fasting blood glucose ((8.9 ± 1.4) mmol/L vs.(6.9 ± 1.0) mmol/L,t =5.951,P ＜0.01),postprandial blood glucose ((14.4 ±1.5) mmol/L vs.(10.4 ± 1.4) mmol/L,t =8.878,P ＜ 0.01)),HbA1 c ((8.7 ± 1.3) ％ vs.(7.6 ± 1.1) ％,t =4.860,P ＜0.01),fasting C peptide ((1.7 ±0.6) mg/L vs.(2.9 ± 1.1) mg/L,t =5.752,P ＜ 0.01) and postprandial2 h C peptide ((5.0 ±2.3) mg/L vs.(10.2 ±3.5) mg/L,t =5.667,P ＜0.01) after treatment.Significant change of blood liquid and body weight were also observed after treatment than before treatment (P ＜ 0.01).Conclusion Liraglutide treatment resulted in persistent better glycaemic control,weight reduction,improvements of blood lipid and function of pancreatic island successfully.Liraglutide was also associated with low risk of hypoglycemic and should be chosen by patients with T2DM.
